Structure via PubChem · Public domain (PubChem)
nafamostat
Sign in to saveAlso known as FUT-175, Nafamostat mesilate, Nafamostat dimethanesulfonate
Nafamostat mesylate (INN), a synthetic serine protease inhibitor, is a short-acting anticoagulant, and it is also used for the treatment of pancreatitis. It also has some potential antiviral and anti-cancer properties. Nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. The mechanism of action of nafamostat is as a slow tight-binding substrate, trapping the target protein in the acyl-enzyme intermediate form, resulting in apparent observed inhibition.
Chemical data
- Formula
- C19H17N5O2
- Molecular weight
- 347.4 g/mol
- IUPAC name
- (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
- SMILES
- C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
- InChIKey
- MQQNFDZXWVTQEH-UHFFFAOYSA-N
- XLogP
- 2
- Polar surface area
- 141 Ų
- H-bond donors
- 4
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- Acute kidney injury, COVID-19
via ChEMBL · EBI
Research
1,061 papers- Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis.Critical care (London, England) · 2025
- Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.Clinical pharmacokinetics · 2022
- Anticoagulation with nafamostat mesilate during extracorporeal life support.International journal of cardiology · 2022
- Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials.Medicine · 2023
- Nafamostat Reduces the Incidence of post-ERCP Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Clinical pharmacology and therapeutics · 2024
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 347.138225
- Has use
- medication
Show 3 more facts
- chemical formula
- C₁₉H₁₇N₅O₂
- canonical SMILES
- C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
- Commons category
- Nafamostat
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
1 sectionsContents
- References
{{Drugbox | Verifiedfields = changed | verifiedrevid = 444083240 | drug_name = Nafamostat mesylate | type = | IUPAC_name = 6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate | image = Nafamostat.svg | image_class = skin-invert-image
| alt = | caption = | tradename = | Drugs.com = | MedlinePlus = | licence_EU = | licence_US = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Rx-only | routes_of_administration = IV
Excerpted from Wikipedia’s “nafamostat” article, available under the CC BY-SA 4.0 licence.